Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$6.87 USD
+0.22 (3.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.85 -0.02 (-0.29%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
VRCA 6.87 +0.22(3.31%)
Will VRCA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VRCA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRCA
Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?
Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel
VRCA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for April 18th
Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up
Corcept (CORT) Down on Q2 Earnings Miss, Revenues Rise Y/Y
Other News for VRCA
Understanding the Miscommunication: Clarifying Requests for Report Summaries
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Verrica Pharma gains as FDA lists Ycanth in Orange Book
Verrica Pharmaceuticals Announces that YCANTHâ„¢ Receives New Chemical Entity Status and Orange Book Listing from the FDA
Verrica announces YCANTH receives new chemical entity status